Sichuan Food and Drug Administration reported that no product quality problems have been found

Business News Agency May 30th In response to the recent public opinion concerns of Suizhong Pharmaceutical Co., Ltd., the Sichuan Food and Drug Administration held a news briefing in Chengdu. According to Wei Xihe, deputy director of Sichuan Provincial Bureau and spokesman of the press, Yuzhong Pharmaceutical Co., Ltd. has violated the GMP problem in the production process of traditional Chinese medicines and was ordered to suspend production for rectification. As of now, no company has found product quality problems.

Suizhong Pharmaceutical Co., Ltd. is located in Deyang City and owns 99 varieties of national drug standards. In 2010, its sales revenue was 2.5 billion yuan. Since May 20 this year, some domestic newspapers and websites have continuously reported that Suizhong Pharmaceutical had suspended production and rectification due to alleged counterfeiting and quality problems. The reporter learned from the briefing session that in April this year, the State Food and Drug Administration and the Sichuan Provincial Bureau discovered during the on-site inspection of Suizhong Pharmaceutical that there were violations of GMP regulations in the production process of the company's traditional Chinese medicines, such as the cleanroom workshop. There are ground damage and wall cracks; some facilities and equipment are obsolete, maintenance and maintenance are not timely; production records are incomplete; extraction workshops are not effective to prevent insects from entering facilities; waste from production sites is not timely treated. The Sichuan Provincial Bureau required the company's Chinese medicine workshop to immediately stop production and rectification.

According to Wei Xihe, according to the results of the daily supervision and selective testing of Suizhong Pharmaceutical in the past two years, as of now, no quality problems have been found in the Chinese medicine varieties of the company. At present, Sichuan Provincial Bureau of Food and Drug Administration and Deyang Food and Drug Administration are urging enterprises to suspend production and rectification for the irregular behaviors existing in the production of Chinese medicine in Suizhong Pharmaceutical. Sichuan Provincial Bureau Supervision Group is supervising local government organizations to conduct further investigations. If new progress is made in the investigation, it will be announced to the society in a timely manner; problems existing in the company will be strictly handled according to the investigation results.

At the ventilation meeting, in response to doubts of some media, the Sichuan Provincial Bureau unequivocally replied that in the April inspections and post-inspection supervision and rectification, neither the production records nor the on-site inspection found the fact that Suizhong Pharmaceutical used substitute materials. (Reporter Yu Hongyan reports)